Leap therapeutics to present updated data from part a of the distinguish study of dkn-01 plus tislelizumab and chemotherapy in gastric cancer patients at the 2023 asco annual meeting

19.5 months median os in the overall first-line patient population, exceeding current benchmarks long-term follow-up identifies additional patient with partial response, resulting in 73% orr in overall mitt population, including 86% orr in pd-l1-low patients cambridge, mass. , may 25, 2023 /prnewswire/ -- leap therapeutics, inc. (nasdaq: lptx), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the company will be presenting new long-term follow-up data in first-line patients with advanced gastric or gastroesophageal junction adenocarcinoma (gea) from part a of the distinguish study, a phase 2 clinical trial evaluating leap's anti-dickkopf-1 (dkk1) antibody, dkn-01, in combination with beigene's tislelizumab and chemotherapy, at the upcoming 2023 american society of clinical oncology (asco) annual meeting taking place in chicago, il on june 2-6, 2023.
LPTX Ratings Summary
LPTX Quant Ranking